Department of Psychology, University of New Mexico, MSC 03-2220, Albuquerque, NM, 87131, USA.
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
J Gen Intern Med. 2021 Feb;36(2):404-412. doi: 10.1007/s11606-020-06331-x. Epub 2020 Nov 12.
The World Health Organization (WHO) categorizes alcohol consumption according to grams consumed into low-, medium-, high-, and very-high-risk drinking levels (RDLs). Although abstinence has been considered the ideal outcome of alcohol treatment, reductions in WHO RDLs have been proposed as primary outcomes for alcohol use disorder (AUD) trials.
The current study examines the stability of WHO RDL reductions and the association between RDL reductions and long-term functioning for up to 3 years following treatment.
Secondary data analysis of patients with AUD enrolled in the COMBINE Study and Project MATCH, two multi-site, randomized AUD clinical trials, who were followed for up to 3 years post-treatment (COMBINE: n = 694; MATCH: n = 806).
Alcohol use was measured via calendar-based methods. We estimated all models in the total sample and among participants who did not achieve abstinence during treatment.
One-level RDL reductions were achieved by 84% of patients at the end of treatment, with 84.9% of those individuals maintaining that reduction at a 3-year follow-up. Two-level RDL reductions were achieved by 68% of patients at the end of treatment, with 77.7% of those individuals maintaining that reduction at a 3-year follow-up. One- and two-level RDL reductions at the end of treatment were associated with significantly better mental health, quality of life (including physical quality of life), and fewer drinking consequences 3 years after treatment (p < 0.05), as compared to no change or increased drinking.
AUD patients can maintain WHO RDL reductions for up to 3 years after treatment. Patients who had WHO RDL reductions functioned significantly better than those who did not reduce their drinking. These findings are consistent with prior reports suggesting that drinking reductions, short of abstinence, yield meaningful improvements in patient health, well-being, and functioning.
世界卫生组织(WHO)根据摄入的克数将饮酒量分为低危、中危、高危和极高危饮酒水平(RDL)。虽然戒酒被认为是酒精治疗的理想结果,但WHO RDL 的降低已被提议作为酒精使用障碍(AUD)试验的主要结果。
本研究旨在检验 WHO RDL 降低的稳定性,以及治疗后长达 3 年期间 RDL 降低与长期功能之间的关系。
对参加 COMBINE 研究和 MATCH 项目的 AUD 患者进行二次数据分析,这两项是多地点、随机 AUD 临床试验,患者在治疗后最多随访 3 年(COMBINE:n=694;MATCH:n=806)。
通过基于日历的方法测量酒精使用情况。我们在总样本中以及在治疗期间未达到戒酒的参与者中估计了所有模型。
治疗结束时,84%的患者达到了 RDL 一级降低,其中 84.9%的患者在 3 年随访时维持了这一降低。治疗结束时,68%的患者达到了 RDL 二级降低,其中 77.7%的患者在 3 年随访时维持了这一降低。治疗结束时的 RDL 一级和二级降低与治疗后 3 年心理健康状况显著改善、生活质量(包括身体生活质量)显著提高以及饮酒后果减少相关(p<0.05),与无变化或饮酒增加相比。
AUD 患者在治疗后长达 3 年内可以维持 WHO RDL 降低。与未减少饮酒的患者相比,RDL 降低的患者功能显著改善。这些发现与先前的报告一致,表明减少饮酒,即使没有达到戒酒,也能显著改善患者的健康、幸福和功能。